In just three days of a phase I trial, Idenix’s experimental, nucleotide-containing Hepatitis C drug (IDX184) demonstrates excellent safety and antiviral activity.<\/p>\n
Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis
\nC Virus (HCV)<\/p>\n
CAMBRIDGE, Mass., Oct. 30 \/PRNewswire-FirstCall\/ — Idenix Pharmaceuticals,
\nInc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and
\ndevelopment of drugs for the treatment of human viral diseases, today
\nannounced presentations of data on IDX184, a once-daily novel liver-targeted
\nnucleotide prodrug of 2′-methyl guanosine (2’MeG) for the treatment of HCV, at
\nthe annual meeting of the American Association for the Study of Liver Diseases
\n(AASLD) currently being held in Boston, Massachusetts. <\/p>\n
Data from a three-day, phase I proof-of-concept study evaluating the safety
\nand antiviral activity of IDX184 will be presented. This double-blind,
\nplacebo-controlled, monotherapy, dose-escalation study enrolled 41
\ntreatment-naive HCV genotype 1-infected patients into four dosing cohorts (25
\nmg, 50 mg, 75 mg and 100 mg). IDX184 was well tolerated in this study with no
\nserious adverse events reported and no discontinuations from the study.<\/p>\n